Diabetes

Panelists discuss discusses how delayed intervention in Stage 2 Type 1 diabetes can accelerate beta cell destruction, leading to more severe clinical onset and increased risk of life-threatening complications like diabetic ketoacidosis.

Panelists discuss how Type 1 diabetes progresses through distinct stages, beginning with asymptomatic autoantibody presence, followed by abnormal blood sugar levels, and ultimately manifesting with classic symptoms like excessive thirst, frequent urination, and unexplained weight loss.

Panelists discuss how early screening for Type 1 diabetes involves testing for autoantibodies in at-risk individuals, particularly those with family history or genetic predisposition, to enable prompt intervention and reduce the risk of diabetic ketoacidosis at diagnosis.

Panelists discuss how managing Type 1 diabetes requires constant vigilance through blood sugar monitoring, insulin administration, and lifestyle adjustments to maintain healthy glucose levels throughout daily life.

Panelists discuss how Type 1 diabetes imposes significant physical, emotional, and financial burdens on patients through the lifelong need for insulin therapy, blood glucose monitoring, lifestyle modifications, and management of potential complications.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Panelists discuss how teplizumab infusion requires specialized medical facilities equipped to manage intravenous therapy, monitor for potential adverse effects, and provide appropriate care during treatment to ensure patient safety and efficacy.

Panelists discuss how teplizumab, an anti-CD3 monoclonal antibody, delays the onset and progression of type 1 diabetes by modulating immune response and preserving ß-cell function in high-risk individuals.

Panelists discuss screening for T1D for individuals at higher risk, such as those with a family history of T1D, autoimmune conditions, or certain genetic markers, to identify early signs of the disease and enable timely intervention.

Panelists discuss how antibody screening tests for type 1 diabetes (T1D), including tests for insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) antibodies, and other markers can help identify individuals at risk for developing the disease before clinical symptoms appear, enabling earlier monitoring and potential intervention.

Panelists discuss how delaying intervention in stage 2 type 1 diabetes, when dysglycemia is present but clinical symptoms have not yet developed, can lead to further ß-cell deterioration and worsen long-term glycemic control, ultimately increasing the risk of complications.

Panelists discuss how the progression of type 1 diabetes unfolds through distinct stages, from the preclinical phase of autoimmunity to the onset of clinical diabetes, emphasizing the importance of early detection and intervention to improve patient outcomes.

Panelists discuss how adhering to screening guidelines for type 1 diabetes enables early detection and intervention, improving patient outcomes and delaying disease progression through timely treatments like teplizumab.

Panelists discuss how managing the clinical, financial, and quality-of-life burdens of type 1 diabetes (T1D) requires early intervention, proactive care strategies, and the use of treatments like teplizumab to improve patient outcomes and reduce long-term complications.

About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.

A quick review of the scope of diabetes in the US and of the gaps in equitable access to care supports the annual call to action from the International Diabetes Federation.

Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.

Experts on diabetes provide insights gleaned from the SIMPLE study and outline patient factors that inform treatment decisions.

Medha Munshi, MD, leads a comprehensive discussion on diabetes treatment practices and discusses the role of deprescribing and other treatment adjustments in older adult patients.

Continuing the discussion on a 68-year-old patient, the panel discusses the importance of follow-up and the benefits of combination therapies in older adults.

Focusing on diabetes testing and treatment practices, Conan Tu, MD, MBA, DACD, BC-ADM, presents the profile of a 68-year-old new patient who presents with symptoms in line with a family history of type 2 diabetes.

Conan Tu, MD, MBA, DACD, BC-ADM, presents a case of an 84-year-old patient with diabetes experiencing medication burden and glycemic control challenges.